Total Payments
$109,751
2024 Payments
$274.28
Companies
14
Transactions
148
Medicare Patients
1,058
Medicare Billing
$96,205
Payment Breakdown by Category
Other$60,485 (55.1%)
Consulting$42,452 (38.7%)
Travel$4,020 (3.7%)
Food & Beverage$2,356 (2.1%)
Education$438.11 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60,485 | 21 | 55.1% |
| Consulting Fee | $42,452 | 15 | 38.7% |
| Travel and Lodging | $4,020 | 28 | 3.7% |
| Food and Beverage | $2,356 | 74 | 2.1% |
| Education | $438.11 | 10 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $77,586 | 66 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $19,976 | 32 | $0 (2018) |
| Genentech USA, Inc. | $5,824 | 16 | $0 (2024) |
| Acorda Therapeutics, Inc | $5,106 | 5 | $0 (2017) |
| TG Therapeutics, Inc. | $684.24 | 2 | $0 (2024) |
| ABBVIE INC. | $239.18 | 12 | $0 (2024) |
| Genentech, Inc. | $114.00 | 3 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $61.44 | 3 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $51.22 | 3 | $0 (2024) |
| EMD Serono, Inc. | $32.93 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $274.28 | 10 | ABBVIE INC. ($94.17) |
| 2023 | $158.55 | 9 | Genentech USA, Inc. ($61.76) |
| 2022 | $10,528 | 9 | Biogen, Inc. ($10,443) |
| 2021 | $28,341 | 19 | Biogen, Inc. ($27,712) |
| 2020 | $18.84 | 1 | EMD Serono, Inc. ($18.84) |
| 2019 | $25,208 | 27 | Biogen, Inc. ($25,109) |
| 2018 | $19,708 | 27 | Biogen, Inc. ($14,026) |
| 2017 | $25,515 | 46 | Teva Pharmaceuticals USA, Inc. ($19,961) |
All Payment Transactions
148 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $84.24 | General |
| Category: Immunology | ||||||
| 10/16/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Immunology | ||||||
| 09/26/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: Neurology | ||||||
| 07/11/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: NEUROSCIENCE | ||||||
| 07/01/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: NEUROSCIENCE | ||||||
| 06/27/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $30.75 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $27.60 | General |
| Category: NEUROSCIENCE | ||||||
| 02/21/2024 | Biogen, Inc. | AVONEX (Biological), TYSABRI, VUMERITY | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: Neurology | ||||||
| 02/01/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $26.67 | General |
| Category: Neurology | ||||||
| 01/24/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/13/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/29/2023 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $17.62 | General |
| Category: Neurology | ||||||
| 09/06/2023 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: Neurology | ||||||
| 06/28/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: NEUROSCIENCE | ||||||
| 06/13/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: NEUROSCIENCE | ||||||
| 06/06/2023 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Immunology | ||||||
| 05/25/2023 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: Immunology | ||||||
| 03/02/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 02/14/2023 | Genentech USA, Inc. | Enspryng (Biological) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Immunology | ||||||
| 11/14/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: NEUROSCIENCE | ||||||
| 07/19/2022 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,291.00 | General |
| 06/24/2022 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,291.00 | General |
| Category: Neurology | ||||||
| 06/24/2022 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: Neurology | ||||||
| 04/22/2022 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,839.00 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 206 | 266 | $31,012 | $19,512 |
| 2022 | 5 | 245 | 321 | $40,070 | $24,290 |
| 2021 | 5 | 245 | 322 | $41,586 | $26,763 |
| 2020 | 7 | 362 | 409 | $66,994 | $25,640 |
Total Patients
1,058
Total Services
1,318
Medicare Billing
$96,205
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 103 | 141 | $15,537 | $9,200 | 59.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 64 | 85 | $12,505 | $8,551 | 68.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 39 | 40 | $2,970 | $1,762 | 59.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 106 | 146 | $15,892 | $9,851 | 62.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 62 | 88 | $13,030 | $8,686 | 66.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 53 | $3,816 | $2,260 | 59.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $4,182 | $2,136 | 51.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 17 | 17 | $3,150 | $1,358 | 43.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 83 | 116 | $17,283 | $12,980 | 75.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 95 | 129 | $13,893 | $9,306 | 67.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 43 | 46 | $3,478 | $2,089 | 60.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $3,252 | $1,445 | 44.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 13 | 20 | $3,680 | $943.58 | 25.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 72 | 84 | $12,360 | $7,079 | 57.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 67 | 91 | $17,485 | $5,537 | 31.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 59 | 63 | $7,254 | $3,517 | 48.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 35 | 38 | $5,510 | $2,186 | 39.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 16 | 16 | $6,938 | $2,061 | 29.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 14 | 14 | $4,900 | $1,413 | 28.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 39 | 41 | $4,477 | $1,335 | 29.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 23 | 24 | $4,230 | $1,324 | 31.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 23 | 24 | $2,832 | $895.62 | 31.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 14 | 14 | $1,008 | $292.13 | 29.0% |
About Alexandra Degenhardt
Alexandra Degenhardt is a Neurology healthcare provider based in Rockport, Maine. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649378829.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Alexandra Degenhardt has received a total of $109,751 in payments from pharmaceutical and medical device companies, with $274.28 received in 2024. These payments were reported across 148 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($60,485).
As a Medicare-enrolled provider, Degenhardt has provided services to 1,058 Medicare beneficiaries, totaling 1,318 services with total Medicare billing of $96,205. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Rockport, ME
- Active Since 09/20/2006
- Last Updated 01/04/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1649378829
Products in Payments
- TYSABRI (Biological) $35,388
- COPAXONE (Drug) $19,958
- VUMERITY (Drug) $16,134
- TECFIDERA (Drug) $7,979
- OCREVUS (Biological) $5,747
- AMPYRA (Drug) $5,106
- UBRELVY (Drug) $178.48
- BRIUMVI (Drug) $84.24
- Non-Covered Product (Drug) $73.64
- QULIPTA (Drug) $60.70
- NUPLAZID (Drug) $51.22
- Ocrevus (Biological) $40.72
- KESIMPTA (Drug) $40.16
- Rituxan (Biological) $38.00
- PLEGRIDY (Biological) $34.70
- Hizentra (Biological) $21.98
- Enspryng (Biological) $21.04
- Mavenclad (Drug) $18.84
- AVONEX (Biological) $18.51
- Leqembi (Drug) $17.62
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.